drugset
drugset / Trial / NCT04043845

ERK 1/2 Signaling in Ibrutinib Resistant B-cell Malignancies

NCT04043845 ↗

Phase 1 Withdrawn Dana-Farber Cancer Institute Eli Lilly and Company · collab
NaSingle-groupOpen-labelTreatment

Summary

This research is studying the safety of combining ibrutinib with the study drug LY3214996 for chronic lymphocytic leukemia (CLL), Waldenstrom's macroglobulinemia (WM), mantle cell lymphoma (MCL), or marginal zone lymphoma (MZL).

Timeline

Start
2020-02-03
Primary completion
2020-02-03
Completion
2020-02-03

Outcome

Outcome not reported

Stopped (Business): “Business development reasons.”

Drugs

EvaluationDrugModalityDoseRoute
Subject TEMUTERKIB Small molecule — Oral
Background Ibrutinib Small molecule — Oral

Indications

B-cell chronic lymphocytic leukemia Waldenstrom macroglobulinemia mantle cell lymphoma marginal zone lymphoma